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following market authorization of the 13-valent pneumococcal conjugate vaccine 
(PCV13) for adults might be considered. Thus, this study analyzes potential cost-
effectiveness of an adult vaccination with PCV13 from the point of view of the German 
social health insurance. METHODS: In a cross-sectional steady state Markov model, 
efﬁ cacies of the vaccines on invasive pneumococcal diseases (IPD), and community-
acquired pneumonia (CAP, treated in either a hospital or a nonhospital setting) were 
calculated. a steady state is deﬁ ned as a setting in which the whole population (includ-
ing new entrants) is vaccinated as recommended. The modeling of PPV23 and PCV13 
distinguished between risk groups and both vaccines were compared to non-vaccina-
tion. Data on PCV13 were derived from published results on the 7-valent pneumococ-
cal conjugate vaccine (PCV7). The effectiveness of individual pneumococcal 
vaccination of adults was adjusted for expected herd immunity effects of a pediatric 
vaccination with PCV. Utilization of health care services and unit costs were taken 
from publicly accessible data bases. RESULTS: Compared to PPV23, PCV13 revealed 
the potential to avoid a greater number of yearly cases and deaths due to IPD and 
CAP in Germany. For PCV13 it can be expected that monetary savings, resulting e.g. 
from less hospitalization, compensate the costs of the vaccination program. The 
preliminary version of the model concludes that the cost-beneﬁ t ratio is 1.16, i. e. c1 
spend on vaccination saves c1.16 treatment cost. CONCLUSIONS: Our model shows 
that the health economic beneﬁ t of an immunization of adults with PCV13 can be 
expected to be higher than that of PPV23.
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OBJECTIVES: To examine the health and economic impact of PHiD-CV in the public 
sector of Hong Kong compared to no vaccination. METHODS: A Markov analytical 
model modiﬁ ed from the recent Cost-effectiveness Cohort Model for Synﬂ orix (COSY 
Model by HE-group, GCRD, GSK bio, Wavre, Belgium, 2010) was used for the 
analysis of the outcomes of vaccination. The cohort model simulates in a birth cohort 
of 82,100 newborns the disease process of invasive disease (ID) (meningitis and 
bacteremia), community acquired pneumonia (CAP), and acute otitis media (AOM) 
over life-time caused by S pneumoniae and Non-typeable H inﬂ uenzae (NTHi) within 
‘monthly’ cycles. Superimposed on the disease process is integrated in the model its 
disease management expressed in hospitalization rates, medical visits, and speciﬁ c 
interventions such as myringotomies. The epidemiology and disease management is 
Hong Kong speciﬁ c. The study was performed from a health care payer’s perspective. 
RESULTS: The study shows for a 4-dose regimen of PHiD-CV compared to no vac-
cination over a period of 100 years: a gain of 234 quality-adjusted-life-years (QALY); 
an avoidance of 16 cases of IPD, 873 cases of pneumonia, 26,746 cases of AOM and 
25,885 sequelae. Using a 5% discount for cost and beneﬁ ts, cost/QALY gained was 
estimated to be HKD261,492. CONCLUSIONS: With GDP per capita of Hong Kong 
being HKD233,060 in 2009, our study results suggest PHiD-CV vaccination is cost-
effective in providing protection to the people of Hong Kong based on the WHO 
recommended thresholds for cost-effectiveness.
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OBJECTIVES: To evaluate cost-effectiveness of routine pneumococcal vaccination 
with 10-valent pneumococcal non-typeable Haemophilus inﬂ uenzae protein-D vaccine 
(PHiD-CV) compared with 13-valent pneumococcal conjugate vaccine (PCV-13) and 
no vaccination. METHODS: A Markov cohort model with a 100-year time horizon 
was developed to project the impact of vaccination on the incidence of pneumococcal 
and non-typeable Haemophilus Inﬂ uenzae (NTHi) infections in children and adults. 
Data Sources: Czech Republic-speciﬁ c epidemiological and demographic data and data 
from other country sources. Base-case assumptions include estimates of pneumococcal 
and NTHi infection rates as well as vaccine efﬁ cacy based on published literature. 
Model inputs: payer perspective, 80% vaccine coverage, no herd protection and a (3 
+ 1) vaccination schedule. One-way sensitivity analyses performed to assess the impact 
of changes in key model assumptions. RESULTS: PHiD-CV and PCV-13 are projected 
to prevent more cases of invasive disease (89 and 92 respectively) and pneumonia 
hospitalizations (738 and 760 respectively) compared with no vaccination. PHiD-CV 
and PCV-13 are projected to prevent additional GPP/ENT visits due to acute otitis 
media (AOM) (7851 and 3838 respectively) compared with no vaccination strategy. 
The total number of cases of invasive disease was comparable for both vaccines but 
PHiD-CV is estimated to prevent more than 14 000 cases of AOM in comparison 
with PCV-13. Vaccinating a birth cohort with PHiD-CV is expected to generate 75.5 
more QALYs and 5.9 LYG compared to PCV-13. Under vaccine price parity assump-
tions, estimated total savings for health care system are 10.2 mil CZK or 395.6 k EUR 
for PHiD-CV compared to PCV-13 respectively. Sensitivity analyses indicate that 
AOM efﬁ cacy and incidence of AOM related GPP/ENT visits have biggest impact on 
results. CONCLUSIONS: Overall, PHiD-CV is expected to have better quality of life 
impact than PCV-13. Under price parity assumptions, PHiD-CV dominates PCV-13 
because it also has a larger cost offsets.
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OBJECTIVES: In contrast to commonly used discrete-time Markov models, we devel-
oped a more realistic continuous-time multi-stage Markov model to evaluate long-term 
clinical and economic outcomes of raltegravir in treatment naïve HIV-1 patients. 
METHODS: The multi-stage cost-effectiveness model incorporating 3 lines of therapy 
was developed using differential equations and was solved in Mathematica® 6.0. The 
analysis was conducted from the perspective of the National payer in Portugal. a 
typical patient enters the model in a given health state, transitions to another health 
state, can develop acquired immunodeﬁ ciency syndrome (AIDS)/ coronary heart 
disease (CHD)/other adverse events or die. Eighteen health states were deﬁ ned based 
on CD4 and HIV RNA levels. We used the maximum likelihood method to estimate 
matrices of instantaneous transition rates corresponding to the efﬁ cacy of the included 
therapies. Six multi-stage treatment strategies depicting clinical practice in Portugal 
were evaluated. The model outputs included projected number of AIDS and CHD 
events, life expectancy and incremental cost-effectiveness ratios (ICER). The model 
was evaluated for internal and external validity and extensive sensitivity analyses were 
conducted. RESULTS: The predicted prevalence of patients in different health states 
over time provided a good ﬁ t to the clinical trial data. Strategies where raltegravir was 
included in the initiating therapy followed by an NNRTI or PI based regimen against 
efavirenz or PI based initiating therapies followed by raltegravir resulted in longer 
undiscounted life expectancy [20.07 Yrs. vs. 18.88 Yrs] and demonstrated cost-
effectiveness [ICERs: c1,078–c33,406/QALY]. CONCLUSIONS: Continuous-time 
Markov modeling based on transition matrices estimated using robust statistical 
methodology is a more realistic and sound approach. Results suggest initiating therapy 
on raltegravir generated lower costs and higher survival versus saving the drug for 
later lines of therapy in Portugal.
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OBJECTIVES: To assess clinical efﬁ cacy and economic effectiveness of Azithromycin 
compared with other antibiotics for community-acquired pneumonia (CAP) and sinus-
itis treatment. METHODS: Decision tree was used to calculate costs of antibiotic 
treatment. The chance nodes included treatment failures and introduction of second-
line therapy or hospitalization. Transition probabilities were obtained from clinical 
trials. Preferred antibiotics for comparison with azithromycin(extended release, 2.0 
g.) and for second-line treatment were chosen by experts in a survey. Medical care 
costs were derived from Moscow mandatory medical insurance system. Costs of the 
medications were obtained from consumer prices database. Sensitivity analysis was 
carried out. RESULTS: Clinical efﬁ cacy was equal. Costs of CAP treatment were 4390 
rub (142.14$) for Amoxycillin and clavulanic acid, 5386 Rub ($174.39) for Cefurox-
ime axetil and 4053 Rub ($131.23) for Azithromycin. Costs of sinusitis treatment 
were 3637(117.76), 3728 (120.71) and 3570 rub ($115,59) for Amoxycillin and 
clavulanic acid, Cefuroxime axetil and Azithromycin respectively. CONCLUSIONS: 
Azithromycin is more efﬁ cient option for CAP and sinusitis treatment than Cefuroxime 
axetil and Amoxycillin and clavulanic acid in Russia.
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OBJECTIVES: To simulate the potential beneﬁ ts of implementing infant vaccination 
with the 10-valent pneumococcal & non-typeable Haemophilus inﬂ uenzae (NTHi)-
protein D conjugate vaccine (PHiD-CV) or the 13-valent pneumococcal conjugate 
vaccine (PCV13) in Latin American countries. METHODS: Vaccine impact was 
assessed using a Markov cohort model for Mexico, Brazil, Chile, and Colombia. The 
model simulates the burden of pneumococcal- and NTHi-related diseases (Invasive 
Disease (ID), Community Acquired Pneumonia (CAP) and Acute Otitis Media (AOM)) 
in a birth cohort followed over a lifetime. Epidemiology, disease management and 
costs are country-speciﬁ c. Vaccination schemes (3 + 1) at 90% coverage & price parity 
were compared to no intervention. Future QALYs and costs discounted at 3.5%, using 
the health care payer perspective are presented. RESULTS: Mortality impact on ID 
and CAP for the two vaccines is projected to be comparable under base-case conditions 
which include minimum assumptions of NTHi infection rates. Vaccines are predicted 
